Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-1827
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma ; volume:124 ; number:1 ; day:7 ; month:10 ; year:2020 ; pages:237-246 ; date:1.2021
British journal of cancer ; 124, Heft 1 (7.10.2020), 237-246, 1.2021
- Creator
-
Lee, Chung-Han
Motzer, Robert J.
Glen, Hilary
Michaelson, M. D.
Larkin, James
Minoshima, Yukinori
Kanekiyo, Michio
Ikezawa, Hiroki
Sachdev, Pallavi
Dutcus, Corina E.
Funahashi, Yasuhiro
Voß, Martin Henner
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-020-01092-0
- URN
-
urn:nbn:de:101:1-2021020611175554089997
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lee, Chung-Han
- Motzer, Robert J.
- Glen, Hilary
- Michaelson, M. D.
- Larkin, James
- Minoshima, Yukinori
- Kanekiyo, Michio
- Ikezawa, Hiroki
- Sachdev, Pallavi
- Dutcus, Corina E.
- Funahashi, Yasuhiro
- Voß, Martin Henner
- SpringerLink (Online service)
Other Objects (12)
Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane
CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors
The Development of Lenvatinib-Induced Pancreatitis in a Patient with Metastatic Neuroendocrine Tumor: A Case Report
Reanalyzing German correlative "es"
Sichere Anwendung von Everolimus
Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane
CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors
The Development of Lenvatinib-Induced Pancreatitis in a Patient with Metastatic Neuroendocrine Tumor: A Case Report
Reanalyzing German correlative "es"
Sichere Anwendung von Everolimus
Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane
CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors
The Development of Lenvatinib-Induced Pancreatitis in a Patient with Metastatic Neuroendocrine Tumor: A Case Report
Reanalyzing German correlative "es"